BioInvent extends license agreement with Bayer to develop antibodies News-Medical.net BioInvent International AB (OMXS: BINV) today announces that it has signed an extension to its 2008 license agreement with Bayer Pharma AG for the development of antibodies from BioInvent's n-CoDeRĀ® libraries. Under the terms of the extension, Bayer ... BioInvent and Bayer extend and broaden collaboration for the discovery and ... |
